M&A analysis: Genmab bucks the bargain basement trend
The group’s $8bn acquisition of Merus was the standout in the third quarter.
Gilead gets into in vivo Car-T
Interius, one of the most advanced players, will cost $350m.
How to be different in in vivo Car-T
After Astra's EsoBiotec takeover the battle for uniqueness begins.
Astra gives in vivo Car-T its biggest endorsement
The company buys Belgium’s EsoBiotec for $425m.
In vivo Car-T gains traction
Clinical expansion shows regulators getting comfortable with in vivo-generated cell therapy.
Blood cancer gene therapies enter the clinic
First-in-human trial initiations feature Interius, Umoja and Vironexis.
Umoja and AbbVie chase Interius with in vivo Car-T
The companies hope to be as efficacious as ex vivo therapy, with convenience and safety advantages.
